Search
Biodexa Pharmaceuticals PLC
BDRXAdd to Watchlist
2.940USD
-0.060-2.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.33MMarket Cap
16.87P/E TTM
More Details of Biodexa Pharmaceuticals PLC Company
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLC Info
Ticker SymbolBDRX
Company nameBiodexa Pharmaceuticals PLC
IPO dateDec 08, 2014
CEOStamp (Stephen A)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endDec 08
Address1 Caspian Point
CityABINGDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeCF10 4DQ
Phone4401235888300
Websitehttps://www.biodexapharma.com/
Ticker SymbolBDRX
IPO dateDec 08, 2014
CEOStamp (Stephen A)
Company Executives of Biodexa Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
FAQs
Who are the top five shareholders of Biodexa Pharmaceuticals PLC?
The top five shareholders of Biodexa Pharmaceuticals PLC are: Dr. Simon Turton
How many institutions hold shares of Biodexa Pharmaceuticals PLC (BDRX)?
As of 2026Q1, 26 institutions hold shares of Biodexa Pharmaceuticals PLC, with a combined market value of approximately 66.51K, accounting for 7.79% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 60313.00.